Giving New Life to Damaged Hearts: Advanced Surgical Treatment for Heart Failure

ORLANDO, FL November 12 2003 – During the 2003 American Heart Association Scientific Sessions, leading heart experts from around the world predict the emerging TRISVR™ (tri-saver) surgical ventricular restoration procedure will be a standard of care for patients suffering with congestive heart failure. Participants in the round table discussing current heart failure treatments included moderator John Strobeck, M.D., Ph.D, co-editor of Congestive Heart Failure and Chief of Cardiology at The Valley Hospital; Stephen Boyce, M.D., of Washington Hospital Center; John Conte, M.D., of Johns Hopkins Hospital; Maria Rosa-Costanzo, M.D., of Midwest Heart Associates; and Marisa DiDonato, M.D. of Istituto Policlinico San Donato.

"I urge my fellow colleagues to consider treatment options such as the TRISVR procedure when current therapies are not working," says cardiologist Dr. Maria Rosa-Costanzo, Midwest Heart Associates, Naperville, IL. "A large portion of heart failure patients are being underserved, and need to be considered for options beyond conventional approaches."

According the American Heart Association, congestive heart failure, usually caused by a prior heart attack, is a fatal disease diagnosed in about 5 million people each year in the United States. In 2010, the number of people diagnosed is expected to increase by 40%. Recent studies also indicate one-third of heart failure patients receive inadequate care. Chase Medical, developer of the MannequinTM shaping device used in the TRISVR operation, reports almost 1.6 million patients suffering from congestive heart failure could benefit from the procedure in the US alone.

Heart failure patients have traditionally been managed with medications prescribed to treat symptoms such as angina, fatigue and shortness of breath. The TRISVR procedure is designed to treat the problem causing the symptoms. The problem develops because the left ventricle, or main pumping chamber of the heart, becomes weakened from an injury such as a heart attack. The ventricle, now enlarged, out of shape and stretched thin, is not able to pump blood properly through the body. The MannequinTM, the first medical device designed to reshape and resize the damaged heart back to a more normal shape and size, allows cardiac surgeons to standardize the procedure, and significantly improve the heart's ability to pump blood more effectively.

The participants in the round table examined the benefits from emerging treatments for heart failure, including the TRISVR procedure; as well as the long term results of surgical ventricular restoration compared to medical therapy and traditional bypass surgery. Doctors reviewed data supporting the importance of reshaping and resizing the damaged heart muscle to improve its ability to pump more effectively. The roundtable discussion also included the evolution of surgical ventricular restoration, beginning with Dr. Denton Cooley in 1958.

Chase Medical located in Richardson, Texas, is a privately held company dedicated to providing innovative technological advancements and educational programs that will improve the delivery of therapies to millions of patients suffering from congestive heart failure. The Chase Medical TRISVR(tm) System, including the Mannequin(tm) Endoventricular Shaping Device, is FDA cleared for market in the United States, and has also received CE Marking and is marketed in Europe.

For more information about congestive heart failure, log onto www.congestiveheartfailure.net. For information about Chase Medical and Chase Medical products, please visit the company's website at www.chasemedical.com.

-



This article courtesy of http://hearthealthysite.com.
You may freely reprint this article on your website or in
your newsletter provided this courtesy notice and the author
name and URL remain intact.

Submit Your Article